The Wall Street Journal reviews the slate of mid-stage therapies in clinical trials for obesity. While the market for new therapies is huge, the challenges involved in developing a therapy that's safe, effective and free of embarrassing side effects have been vexing for the R&D crowd.

Among the most promising therapies in the pipeline: Novo Nordisk's liraglutide [1], which triggered weight loss of more than 5 percent in 75 percent of Phase II volunteers; Amylin Pharmaceuticals' combo of pramlintide and metreleptin, which triggered an average weight loss of 12.7 percent in 177 Phase II volunteers; and Arena Pharmaceuticals' lorcaserin [2], which is going into Phase III.  

- read the article [3] from the Wall Street Journal

Related Articles:
Biotechs discuss obesity therapies at BIO [3]
Obesity drugs pose weighty problems for researchers [4]
Fat cell research points to new approach on obesity [5]